Search Results
51 Results for 'Vaccines'
PAGE 2 OF 3
Technology
Generation Of Infectious Influenza Viruses From Virus-Like Particles
Compositions and methods to prepare influenza virus-like particles (VLPs) are provided.
Learn More
Learn More
Yoshihiro Kawaoka, Gabriele Neumann | P150373US02
Technology
Mini-Intronic Plasmid Dna Vaccines In Combination With Lag3 Blockade
It is disclosed herein that (a) an anti-tumor DNA vaccine delivered using a MIP DNA vector is a less effective tumor treatment than the corresponding anti-tumor DNA vaccine delivered using a conventio...
Learn More
Learn More
Douglas McNeel, Viswa Colluru | P150088US02
Technology
Vaccines Comprising Mutant Attenuated Influenza Viruses
The invention provides a vaccine comprising an effective amount of an isolated recombinant influenza virus comprising a mutant M gene segment that is mutated so that upon viral replication the mutant ...
Learn More
Learn More
Yoshihiro Kawaoka, Shinji Watanabe, Tokiko Watanabe | P100251US02
Technology
Recombinant Influenza Viruses With Stabilized Ha For Replication In Eggs
Modified influenza virus neuraminidases are described herein that improve viral replication, thus improving the yield of vaccine viruses. Expression of such modified neuraminidases by influenza virus ...
Learn More
Learn More
Yoshihiro Kawaoka, Shinya Yamada, Shiho Chiba | P180114US03
Technology
Novel Adjuvant For Animal And Human Vaccines
Quil-A chitosan spherical nanostructure complexes as well as methods of making and using such complexes are disclosed herein. Also provided are Quil-A chitosan spherical nanostrucutres loaded with one...
Learn More
Learn More
Adel Talaat, Shaswath Chandrasekar | P190189US02
Technology
Mutations That Confer Genetic Stability To Additional Genes In Influenza Viruses
The disclosure provides for an isolated recombinant influenza virus having at least one of: a PB2 viral segment encoding PB2 with residue at position 540 that is not asparagine or a residue at positio...
Learn More
Learn More
Yoshihiro Kawaoka, Yuri Furusawa | P190174US02
Technology
Humanized Cell Line
A mammalian or avian cell line that expresses high levels of human influenza virus receptors is provided. In one embodiment, the cell line supports human influenza virus, e.g., human A/H3 influenza vi...
Learn More
Learn More
Yoshihiro Kawaoka, Kosuke Takada, Masaki Imai | P180301US03
Technology
Vectors For Eliciting Immune Responses To Non-Dominant Epitopes In The Hemagglutinin (Ha) Protein
Methods of preparing influenza viruses having altered immunodominant epitopes in HA, e.g., having one or more residues in one or more of antigenic sites A-E in HA altered, and viral vectors, e.g., inf...
Learn More
Learn More
Yoshihiro Kawaoka, Gabriele Neumann, Huihui Kong | P190028US02
Technology
Recombinant Influenza Viruses With Stabilized Ha For Replication In Eggs
Modified influenza virus neuraminidases are described herein that improve viral replication, thus improving the yield of vaccine viruses. Expression of such modified neuraminidases by influenza virus...
Learn More
Learn More
Yoshihiro Kawaoka, Shinya Yamada, Shiho Chiba | P200038US02
Technology
Modified Clostridial Neurotoxins As Vaccines And Conjugate Vaccine Platforms
Provided herein are engineered non-catalytic, non-toxic tetanus toxin variants and methods of using such engineered tetanus toxin variants as low dose, protective vaccines that are non-toxic and more ...
Learn More
Learn More
Eric Johnson, Sabine Pellett, William Tepp, Joseph Barbieri, Amanda Przedpelski | P190179US02
Technology
Improved Influenza Virus Replication For Vaccine Development
An isolated recombinant influenza virus is provided having PA, PB1, PB2, NP, NS, M, NA and HA viral segments, wherein the PB1 viral segment encodes a PB1 with a residue other than isoleucine at positi...
Learn More
Learn More
Yoshihiro Kawaoka, Gabriele Neumann, Jihui Ping | P190171US02
Technology
HLF-VC1 Master Cell Bank for Vaccine Development
FDA-qualified cell lines must be used for virus production for human vaccines. There are relatively few of these lines available and several (WI-38, MRC-5) used for virus production are becoming senes...
Learn More
Learn More
James Gern | P160170US01
Technology
Improved Influenza B Virus Replication for Vaccine Development
The epidemiology of influenza Type B viruses differs from Type A; influenza B viruses primarily circulate in humans and do not cause pandemics. However, in some seasons the impact of influenza B infec...
Learn More
Learn More
Yoshihiro Kawaoka, Gabriele Neumann, Jihui Ping | P160181US02
Technology
Mutations That Improve Genetic Stability of Influenza Virus for Vaccination, Gene Therapy & More
The influenza virus is a highly contagious respiratory pathogen that causes annual epidemics and occasional pandemics. Although many studies have looked at how a host responds to infection with the vi...
Learn More
Learn More
Yoshihiro Kawaoka, Satoshi Fukuyama, Shinji Watanabe | P140264US02
Technology
Influenza Variant Grows Well in CHO Cells
Vaccines against influenza and other viruses can be grown in Chinese Hamster Ovary (CHO) cells. Problematically, an influenza virus that is made by combining H1N1 and PR8 strains, and that is recommen...
Learn More
Learn More
Yoshihiro Kawaoka, Makoto Ozawa | P100246US02
Technology
Neuraminidase-Deficient Live Influenza Vaccine
Influenza infects up to 20 percent of the world’s population every year, causing 500,000 deaths and costing tens of billions of dollars in medical expenses. Influenza A virus, which causes pandemics...
Learn More
Learn More
Yoshihiro Kawaoka, Masato Hatta | P07044US
Technology
Vaccine for Fungal Infections
There are no commercial vaccines against fungi. Infections like aspergillosis and Valley Fever can be life-threatening, particularly in immune-compromised patients. These patients also are more vulner...
Learn More
Learn More
Bruce Klein, Theodore Brandhorst, Thomas Sullivan, Marcel Wuethrich | P130116US02
Technology
Potential for Vaccine Against Johne’s Disease
Johne’s disease, or paratuberculosis, is a chronic and usually fatal wasting disease that is found worldwide and impacts more than half of the dairy herds in the U.S. alone. It costs the ruminant in...
Learn More
Learn More
Adel Talaat | P130200US02
Technology
Safer Ebola Virus and Vaccines
Ebola is the deadliest virus on earth. It has caused death in 90 percent of cases during some outbreaks, afflicting human and great ape populations in tropical Africa. The virus is highly contagious i...
Learn More
Learn More
Yoshihiro Kawaoka, Peter Halfmann, Jin Hyun Kim | P07377US02
Technology
Safer Influenza Vaccine from Replication-Knock Out Virus
Influenza viruses instigate annual global epidemics. The first influenza pandemic in 40 years occurred during the 2009-2010 season, when a novel H1N1 strain emerged and spread worldwide. The United St...
Learn More
Learn More
Yoshihiro Kawaoka, Gabriele Neumann, Makoto Ozawa | P110003US02
Technology
Plasmids Encoding Avian Influenza Genes
Avian influenza causes significant economic losses for poultry producers worldwide and can be transmitted to humans and other mammals. The surface glycoproteins hemagglutinin (HA) and neuraminidase (N...
Learn More
Learn More
Yoshihiro Kawaoka | P06123US
Technology
High Titer Recombinant Influenza Viruses for Vaccines
Influenza is caused by the eight-segmented influenza virus. Vaccines can be used to prevent influenza, but traditional methods for producing influenza vaccine are slow and cumbersome. To generate reco...
Learn More
Learn More
Yoshihiro Kawaoka, Taisuke Horimoto, Shin Murakami | P06370US
Technology
Improved Production of Influenza Virus, Including H1N1, for Vaccine Manufacture
The H1N1 influenza virus, known as the “swine flu,” has been declared a pandemic. While this virus is less virulent than many circulating strains of flu virus, it has become the subject of signi...
Learn More
Learn More
Yoshihiro Kawaoka, Taisuke Horimoto, Shin Murakami | P100078US02
Technology
Attenuated Influenza Viruses for Development of Live Influenza Vaccine
Influenza is a major disease in humans that can be prevented by vaccination. Because new epidemic strains arise every year or two, influenza vaccines must be adapted almost every year. Live attenuat...
Learn More
Learn More
Yoshihiro Kawaoka, Hatice Akarsu, Kiyoko Horimoto | P09022US02
Technology
Cell Line for Evaluating Influenza Virus Sensitivity to NA Inhibitors
The extensive use of neuraminidase (NA) inhibitors to treat influenza virus infections by reducing viral sialidase activity requires close monitoring for resistant variants. However, cultured cells do...
Learn More
Learn More
Yoshihiro Kawaoka | P05278US